Steven Leonard Chapman Sells 2,322 Shares of Natera (NASDAQ:NTRA) Stock

30 Jan 2026, 04:42 by Michael Walen · The Markets Daily

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 2,322 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $240.53, for a total value of $558,510.66. Following the completion of the transaction, the chief executive officer directly owned 216,828 shares of the company’s stock, valued at $52,153,638.84. This represents a 1.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $866,983.68.
On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $373,650.00.
On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $16,885,317.68.
On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.
On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00.
On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88.

Natera Price Performance

NASDAQ NTRA traded down $4.45 during mid-day trading on Thursday, reaching $231.48. The stock had a trading volume of 947,123 shares, compared to its average volume of 1,043,018. The stock has a market cap of $32.02 billion, a PE ratio of -101.08 and a beta of 1.62. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The company has a fifty day moving average price of $235.90 and a 200 day moving average price of $193.29.

Natera (NASDAQ:NTRA – Get Free Report) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the business posted ($0.26) EPS. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. As a group, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price target on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Morgan Stanley boosted their price target on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price objective for the company in a research report on Monday, October 27th. Finally, Guggenheim boosted their target price on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $249.20.

Read Our Latest Stock Analysis on NTRA

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC lifted its holdings in shares of Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC raised its position in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Natera in the second quarter worth $298,000. Finally, Signaturefd LLC raised its holdings in shares of Natera by 10.0% during the second quarter. Signaturefd LLC now owns 1,620 shares of the medical research company’s stock worth $274,000 after purchasing an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

About Natera

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.